XML 76 R14.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Major Customers and Concentration of Credit Risk | 12 Months Ended
--- | ---
Dec. 31, 2014
Risks and Uncertainties [Abstract] |
Major Customers and Concentration of Credit Risk | Major Customers and Concentration of Credit Risk
Customer | 2014 |  | % of Total Revenue |  | 2013 |  | % of Total Revenue |  | 2012 |  | % of Total Revenue
Roche | $ | 7,357,346 |  |  | 70 | % |  | $ | 9,181,759 |  |  | 68 | % |  | $ | — |  |  | — | %
NIAID | 1,229,084 |  |  | 12 |  |  | 2,090,939 |  |  | 16 |  |  | 2,831,115 |  |  | 69 |
GeneOne (affiliated entity) | 479,464 |  |  | 5 |  |  | 425,000 |  |  | 3 |  |  | 577,467 |  |  | 14 |
NIH Research Project Grant | 694,457 |  |  | 6 |  |  | 152,499 |  |  | 1 |  |  | — |  |  | — |
All other | 696,415 |  |  | 7 |  |  | 1,617,149 |  |  | 12 |  |  | 710,070 |  |  | 17 |
Total Revenue | $ | 10,456,766 |  |  | 100 | % |  | $ | 13,467,346 |  |  | 100 | % |  | $ | 4,118,652 |  |  | 100 | %
During the years ended December 31, 2014, 2013 and 2012, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December 31, 2014, $2.3 million or 82% and $190,000 or 7% of accounts receivable was attributed to Roche and the NIAID, respectively. As of December 31, 2013, $2.6 million or 79% and $382,000 or 12% of accounts receivable was attributed to Roche and the NIAID, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration